Today: 9 June 2026
Cipher Mining (CIFR) stock rises premarket as it rebrands to Cipher Digital and leans into data centers

Cipher Mining (CIFR) stock rises premarket as it rebrands to Cipher Digital and leans into data centers

New York, Feb 25, 2026, 07:18 EST — Premarket

  • Cipher Mining climbed roughly 1% in premarket action after announcing its new name: Cipher Digital.
  • The company reports 600 MW of contracted high-performance computing capacity, along with $3.73 billion in project bond financings.
  • Bitcoin miners eye steadier cash flows, putting execution at the Barber Lake and Black Pearl data center sites in sharp focus for investors.

Cipher Mining Inc (CIFR) advanced 1.1% to $17.30 ahead of the open Wednesday, with investors weighing the firm’s pivot from solely bitcoin mining to leasing out data center space for high-performance computing.

This shift carries weight—bitcoin miners have been looking for ways to ease their exposure to wild swings in crypto prices and energy expenses. High-performance computing, or HPC, covers demanding jobs like AI model training and sizable cloud operations.

Cipher says long-term leases can make a miner resemble a contracted infrastructure firm. But there’s a catch: management faces extra pressure to meet construction targets and hold on to tenants, since the cash goes out up front.

Cipher has switched its legal name to Cipher Digital Inc, a filing showed, though the Nasdaq ticker stays “CIFR.” According to the same filing, the company also released an investor presentation dated Feb. 24. SEC

Shares finished Tuesday at $17.12, a gain of $1.90. After the bell, the stock edged up to $17.18, according to MarketWatch data.

Cipher reported fourth-quarter revenue of $60 million and posted an adjusted net loss of $55 million, according to an SEC filing. CEO Tyler Page said the firm is now “officially” operating under the Cipher Digital name, a shift that comes as the company ramps up its focus on HPC data center projects. SEC

Cipher unloaded its 49% stake in three joint venture mining operations—Alborz, Bear, and Chief, each with 40 megawatts of capacity—plus a batch of mining rigs it had running at Black Pearl. The buyer: Canaan Inc, picking it up through an all-stock transaction pegged at roughly $40 million.

During the earnings call, management reported a GAAP net loss of $734.2 million for the quarter, citing a mix of non-cash and transition-related factors. Page dismissed the rebrand as “not an aspirational shift.” CFO Greg Mumford highlighted a $450 million mark-to-market adjustment related to a convertible note derivative, along with impairment charges linked to the company’s legacy mining assets. The Motley Fool

Bitcoin climbed roughly 3.6% in the past 24 hours, trading most recently around $65,530 and, as usual, steering sentiment for miner stocks.

Needham’s John Todaro cut his price target on Cipher to $22 from $26 on Wednesday, but kept his buy rating in place, according to StreetInsider.

But things could just as easily flip. Cipher depends on high-yield debt and aggressive construction timelines. Delays—whether in equipment arrivals, interconnection sign-offs, or getting tenants up to speed—could pressure cash flow, even if bitcoin prices hold up.

Cipher’s investor presentation put both of the signed leases—the 300 MW with AWS, plus another 300 MW with Fluidstack (Google backing up as much as $1.73 billion in Fluidstack commitments)—on track to start in October 2026. The same deck called for roughly $669 million in average annualized net operating income (that’s property-level cash flow, pre-interest and corporate overhead) for the base lease period, and circled the fourth quarter of 2026 for energizing the Stingray site in Texas.

Stock Market Today

  • $150M Cancer Proteomics Deal Spurs New NYSE Listing
    June 9, 2026, 9:34 AM EDT. A $150 million deal in functional proteomics, the study of protein functions and interactions critical for drug development, has led to the spin-out of a new company set to list on the New York Stock Exchange (NYSE). The company focuses on advanced cancer treatments including antibody-drug conjugates-targeted therapies combining antibodies with cell-killing agents to attack tumors precisely. Immunotherapies and targeted therapies featured in the pipeline aim to harness and guide the immune system to combat cancer effectively. Filing of the registration statement with regulators marks a key step toward public investment, enabling transparency. This development highlights the growing financial and clinical importance of proteomics in oncology and the biotech sector.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
MercadoLibre stock set for a rough open after profit miss and margin squeeze hits MELI
Previous Story

MercadoLibre stock set for a rough open after profit miss and margin squeeze hits MELI

Leonardo DRS stock price slips in premarket after 15% surge on earnings, 2026 outlook
Next Story

Leonardo DRS stock price slips in premarket after 15% surge on earnings, 2026 outlook

Go toTop